Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9878921 | Archives of Gerontology and Geriatrics | 2005 | 11 Pages |
Abstract
Depression occurs frequently in post-stroke patients and appears to be associated with an impairment in their rehabilitation and functional recovery. Although selective serotonin reuptake inhibitors (SSRI) are often used in post-stroke depression (PSD), it has been observed that only a subset of patients is responsive to this treatment. Other patients respond to tricyclic antidepressants or MAO inhibitors, which, however, may not have a favorable profile of safety and tolerability in post-stroke patients. In this double-blinded, placebo-controlled study, we evaluated the efficacy and tolerability of the noradrenaline reuptake inhibitor, reboxetine, in a subset of PSD patients classified as affected by “retarded” depression. Reboxetine (4 mg, twice daily, for 16 weeks) was administered to patients that developed depression after a single ischaemic or hemorrhagic stroke. We assessed the severity of depressive symptoms by the Beck Depression Inventory (BDI) and Hamilton Depression Rating Scale (HDRS). HDRS and BDI scores (mean ± S.D.) at baseline were, respectively, 24 ± 1.31 and 19.87 ± 1.46 in the placebo group, 24.06 ± 1.52 and 20.56 ± 2.16 in the reboxetine group. After 16 weeks, HDRS and BDI mean scores were respectively 22.73 ± 2.4 and 18.4 ± 3.33 in the placebo group, 9.26 ± 2.15 and 8.06 ± 3.43 in the reboxetine group [p < 0.01 versus the respective baseline (paired t-test); #p < 0.01 versus retarded depressed patients treated with placebo (one-way analysis of variance (ANOVA) applied to the difference from baseline, associated with Dunnett's t-test to isolate the differences)]. Reboxetine showed a good efficacy, safety and tolerability in PSD patients affected by “retarded” depression. We conclude that reboxetine is well tolerated and may be a useful therapeutic option in PSD patients with “retarded” depression.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Liborio Rampello, Alessandro Alvano, Santina Chiechio, Rocco Raffaele, Ignazio Vecchio, Mariano Malaguarnera,